OrganizationsEmergent Biosolutions, Inc.

Products 1 to 1 of 1

Antibiotic - EV-035 by Emergent Biosolutions, Inc.
Biotech components: Bacteria
Business models: B2C
Country of production: USA
Country of distribution: USA + Switzerland
Intended consumer: Government
Date added: 2018/08/30 11:49 (6 years ago)
Date last modified: 2018/08/30 11:49 (6 years ago)
Known funding amount: 86,000,000 CHF
Funding types: Shareholder Investment
Industry: Health
Market status: Under Development
Organization type(s): Public Company
Product categories: Medical Treatment
Production process: Closed Production
Source: SynBio Database
Trading symbol: EVE (SWX)
Value chain stage: Finished Product